Zhangyong Hong
Overview
Explore the profile of Zhangyong Hong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
646
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu Y, Bai X, Wang H, Wang J, Li S, Zhang H, et al.
Biochem Biophys Res Commun
. 2024 Dec;
742:151155.
PMID: 39662453
Photothermal therapy (PTT) is an innovative cancer treatment that leverages heat generated from near-infrared light exposure to induce tumor cell death. A major challenge in PTT is achieving precise delivery...
2.
Wang X, Ding Y, Li S, Wang F, Yang L, Zhang H, et al.
Int J Pharm
. 2024 Nov;
669():125003.
PMID: 39603436
Immunotoxin has become a highly promising therapy for treating cancer and has achieved good results in preclinical trials targeting various cancers. However, there are still some issues that limit the...
3.
Zheng W, Li S, Shi Z, Su K, Ding Y, Zhang L, et al.
J Nanobiotechnology
. 2024 Sep;
22(1):562.
PMID: 39272180
Background: Tumor neoantigen peptide-based vaccines, systemic immunotherapies that enhance antitumor immunity by activating and expanding antigen-specific T cells, have achieved remarkable results in the treatment of a variety of solid...
4.
Xu K, Han J, Yang L, Cao L, Li S, Hong Z
Int J Mol Sci
. 2023 Jul;
24(13).
PMID: 37446189
Antibody-drug conjugates (ADCs) play important roles in tumor therapy. However, traditional ADCs are limited by the extremely large molecular weight of the antibody molecules, which results in low permeability into...
5.
Jing Z, Wang S, Xu K, Tang Q, Li W, Zheng W, et al.
Adv Sci (Weinh)
. 2022 Jun;
9(24):e2201496.
PMID: 35712770
Therapeutic tumor neoantigen vaccines have been widely studied given their good safety profile and ability to avoid central thymic tolerance. However, targeting antigen-presenting cells (APCs) and inducing robust neoantigen-specific cellular...
6.
Liu H, Meng Z, Wang H, Zhang S, Huang Z, Geng X, et al.
ACS Appl Bio Mater
. 2022 Jan;
4(4):3614-3622.
PMID: 35014447
The use of particulate adjuvants offers an interesting method for enhancing and modulating the immune responses elicited by vaccines. Aluminum salt (Alum) is one of the most important immune adjuvants...
7.
Li J, Wang T, Jiang F, Hong Z, Su X, Li S, et al.
ACS Appl Bio Mater
. 2022 Jan;
4(5):4618-4628.
PMID: 35006799
Photodynamic therapy (PDT) necessitates approaches capable of increasing antitumor effects while decreasing nonspecific photodamage. We herein report an activatable probe (Glu-PyEB) comprising two distinct photosensitizers with mutually suppressed photodynamics. Activation...
8.
Li J, Wang T, Jiang F, Hong Z, Su X, Li S, et al.
J Mater Chem B
. 2021 Jul;
9(29):5829-5836.
PMID: 34254096
Approaches that could enable precise photodynamic therapy (PDT) are of therapeutic potential. We herein report a trifunctional probe (Glu-RdEB) that could be activated to generate fluorescent rhodamine species to pinpoint...
9.
Xing Y, Xu K, Li S, Cao L, Nan Y, Li Q, et al.
Int J Mol Sci
. 2021 Jun;
22(11).
PMID: 34071152
Prostate cancer (PCa) is the second most common cancer in men, causing more than 300,000 deaths every year worldwide. Due to their superior cell-killing ability and the relative simplicity of...
10.
Li Q, Li W, Xu K, Xing Y, Ding Y, Jing Z, et al.
Int J Pharm
. 2021 Apr;
602:120647.
PMID: 33915185
Pancreatic cancer, as one of the most aggressive and lethal malignancies in the world, is lack of effective treatment. Constructing immunotoxin molecules to target the mesothelin (MSLN) receptor is a...